TYK Medicines, Inc
A Study of TY-9591 With Chemotherapy as 1st Line Treatment in Patients With Mutated Epidermal Growth Factor Receptor NSCLC
- Conditions
- Interventions
- First Posted Date
- 2024-11-04
- Last Posted Date
- 2024-11-04
- Lead Sponsor
- TYK Medicines, Inc
- Target Recruit Count
- 60
- Registration Number
- NCT06672068
Studies Evaluating the Effects of Itraconazole or Rifampicin on the Pharmacokinetics of TY-9591 Tablets in Healthy Subjects
- First Posted Date
- 2024-02-13
- Last Posted Date
- 2024-02-26
- Lead Sponsor
- TYK Medicines, Inc
- Target Recruit Count
- 48
- Registration Number
- NCT06255951
- Locations
- 🇨🇳
Yali Liu, Guangdong, Shantou, China
A Study of TYK-00540 in Adult Patients With Solid Tumors
- First Posted Date
- 2024-02-07
- Last Posted Date
- 2024-02-07
- Lead Sponsor
- TYK Medicines, Inc
- Target Recruit Count
- 156
- Registration Number
- NCT06246071
- Locations
- 🇨🇳
Anhui Provincial Hospital, Hefei, China
TY-9591 in the Patients With EGFR Mutations in Advanced NSCLC With Brain Metastases
- Conditions
- Interventions
- First Posted Date
- 2023-07-17
- Last Posted Date
- 2024-11-21
- Lead Sponsor
- TYK Medicines, Inc
- Target Recruit Count
- 420
- Registration Number
- NCT05948813
- Locations
- 🇨🇳
National Cancer Center/Cancer Hospitial,Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, Beijing, China
[14 C] Study on Mass Balance of TY-9591 in Healthy Chinese Subjects
- First Posted Date
- 2023-05-23
- Last Posted Date
- 2023-11-18
- Lead Sponsor
- TYK Medicines, Inc
- Target Recruit Count
- 10
- Registration Number
- NCT05871905
- Locations
- 🇨🇳
Suzhou first people's hospital, Suzhou, Jiangsu, China
A Study of TY-2699a in Patients With Locally Advanced or Metastatic Solid Tumors
- First Posted Date
- 2023-05-19
- Last Posted Date
- 2023-11-07
- Lead Sponsor
- TYK Medicines, Inc
- Target Recruit Count
- 156
- Registration Number
- NCT05866692
- Locations
- 🇨🇳
National Cancer Center/Cancer Hospital, Chinese Academy of Medical Science and Peking Union Medical College, Beijing, Beijing, China
🇨🇳Shandong Cancer Hospital, Jinan, Shandong, China
A Study of TY-2136b in Patients With Advanced Solid Tumors Harboring ALK, ROS1 or NTRK1-3 Alterations
- Conditions
- Interventions
- First Posted Date
- 2023-03-15
- Last Posted Date
- 2023-04-24
- Lead Sponsor
- TYK Medicines, Inc
- Target Recruit Count
- 282
- Registration Number
- NCT05769075
- Locations
- 🇺🇸
Oncology Consultants, Houston, Texas, United States
🇺🇸Rhode Island Hospital, Brown University, Providence, Rhode Island, United States
A Study of TY-1091 in Patients With Advanced Solid Tumors
- Conditions
- Interventions
- First Posted Date
- 2023-01-09
- Last Posted Date
- 2024-01-30
- Lead Sponsor
- TYK Medicines, Inc
- Target Recruit Count
- 248
- Registration Number
- NCT05675605
- Locations
- 🇨🇳
Jinlin Province Cancer Hosipital, Chang chun, Jilin, China
Phase III Study of TY-9591 in Patients With Locally Advanced or Metastatic Non-small Cell Lung Cancer (FLETEO)
- Conditions
- Interventions
- First Posted Date
- 2022-05-19
- Last Posted Date
- 2024-01-30
- Lead Sponsor
- TYK Medicines, Inc
- Target Recruit Count
- 680
- Registration Number
- NCT05382728
- Locations
- 🇨🇳
Hunan Provincial Tumor Hospital, Changsha, Hunan, China
🇨🇳Shanghai Chest Hospital, Shanghai, Shanghai, China
Study of TY-9591 in Patients With a Lung Cancer With Brain or Leptomeningeal Metastases With EGFR Mutation
- Conditions
- Interventions
- First Posted Date
- 2021-12-06
- Last Posted Date
- 2024-01-30
- Lead Sponsor
- TYK Medicines, Inc
- Target Recruit Count
- 60
- Registration Number
- NCT05146219
- Locations
- 🇨🇳
National Cancer Center/Cancer Hospitial,Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, Beijing, China